Prognostic significance of serum proangiogenic molecules in patients with de novo non-hodgkin lymphomas

The Scientific World Journal

Volumn 2012, Issue , 2012, Pages

  Rujirojindakul, Pairaya ^a   Lekhakula, Arnuparp ^a  

^a PRINCE OF SONGKLA UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR RECEPTOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; LACTATE DEHYDROGENASE; PREDNISOLONE; RITUXIMAB; VASCULOTROPIN; VINCRISTINE; ANGIOGENIC PROTEIN; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; FIBROBLAST GROWTH FACTOR 2; PREDNISONE; TUMOR MARKER; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGED; ANEMIA; ARTICLE; BLOOD SAMPLING; CANCER PATIENT; CANCER PROGNOSIS; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; ENZYME IMMUNOASSAY; ETHNIC GROUP; FEMALE; HUMAN; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; SYMPTOM; T LYMPHOCYTE; BLOOD; CLINICAL TRIAL; MIDDLE AGED; MORTALITY; NEOVASCULARIZATION (PATHOLOGY); PREVALENCE; PROGNOSIS; REPRODUCIBILITY; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SURVIVAL; SURVIVAL RATE; THAILAND; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANGIOGENIC PROTEINS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FIBROBLAST GROWTH FACTOR 2; HUMANS; LYMPHOMA, NON-HODGKIN; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PREDNISONE; PREVALENCE; PROGNOSIS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; SURVIVAL RATE; THAILAND; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VINCRISTINE; YOUNG ADULT;

EID: 84861040341     PISSN: None     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1100/2012/215231     Document Type: Article

References (21)

1. Hanahan D., Folkman J., Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis Cell 1996 86 3 353 364 (Pubitemid 26272076)
2. Folkman J., Angiogenesis in cancer, vascular, rheumatoid and other disease Nature Medicine 1995 1 1 27 31
3. Iruela-Arispe M. L., Dvorak H. F., Angiogenesis: a dynamic balance of stimulators and inhibitors Thrombosis and Haemostasis 1997 78 1 672 677 (Pubitemid 27289325)
4. Podar K., Anderson K. C., The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications Blood 2005 105 4 1383 1395 (Pubitemid 40223651)
5. Vacca A., Ribatti D., Roncali L., Ranieri G., Serio G., Silvestris F., Dammacco F., Bone marrow angiogenesis and progression in multiple myeloma British Journal of Haematology 1994 87 3 503 508 (Pubitemid 24230014)
6. Vacca A., Ribatti D., Presta M., Minischetti M., Iurlaro M., Ria R., Albini A., Bussolino F., Dammacco F., Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma Blood 1999 93 9 3064 3073 (Pubitemid 29200799)
7. Kumar S., Witzig T. E., Dispenzieri A., Lacy M. Q., Wellik L. E., Fonseca R., Lust J. A., Gertz M. A., Kyle R. A., Greipp P. R., Rajkumar S. V., Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma Leukemia 2004 18 3 624 627 (Pubitemid 38425879)
8. D'Amato R. J., Loughnan M. S., Flynn E., Folkman J., Thalidomide is an inhibitor of angiogenesis Proceedings of the National Academy of Sciences of the United States of America 1994 91 9 4082 4085 (Pubitemid 24139577)
9. Bartlett J. B., Dredge K., Dalgleish A. G., The evolution of thalidomide and its IMiD derivatives as anticancer agents Nature Reviews Cancer 2004 4 4 314 322 (Pubitemid 38525287)
10. Mangi M. H., Newland A. C., Angiogenesis and angiogenic mediators in haematological malignancies British Journal of Haematology 2000 111 1 43 51
11. Medinger M., Fischer N., Tzankov A., Vascular endothelial growth factor-related pathways in hemato-lymphoid malignancies Journal of Oncology 2010 2010 13
12. Salven P., Teerenhovi L., Joensuu H., A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma Blood 1997 90 8 3167 3172 (Pubitemid 27444212)
13. Salven P., Teerenhovi L., Joensuu H., A high pretreatment serum basic fibroblast growth factor concentration is an independent predictor of poor prognosis in non-Hodgkin's lymphoma Blood 1999 94 10 3334 3339 (Pubitemid 29536126)
14. Salven P., Orpana A., Teerenhovi L., Joensuu H., Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients Blood 2000 96 12 3712 3718
15. Bertolini F., Paolucci M., Peccatori F., Cinieri S., Agazzi A., Ferrucci P. F., Cocorocchio E., Goldhirsch A., Martinelli G., Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma British Journal of Haematology 1999 106 2 504 509 (Pubitemid 29450678)
16. Ribatti D., Vacca A., Nico B., Fanelli M., Roncali L., Dammacco F., Angiogenesis spectrum in the stroma of B-cell non-Hodgkin's lymphomas. An immunohistochemical and ultrastructural study European Journal of Haematology 1996 56 1-2 45 53 (Pubitemid 26075594)
17. Crivellato E., Nico B., Vacca A., Ribatti D., B-cell non-Hodgkin's lymphomas express heterogeneous patterns of neovascularization Haematologica 2003 88 6 671 678 (Pubitemid 36781594)
18. Nguyen M., Watanabe H., Budson A. E., Richie J. P., Hayes D. F., Folkman J., Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers Journal of the National Cancer Institute 1994 86 5 356 361 (Pubitemid 24076875)
19. Brunner G., Nguyen H., Gabrilove J., Rifkin D. B., Wilson E. L., Basic fibroblast growth factor expression in human bone marrow and peripheral blood cells Blood 1993 81 3 631 638 (Pubitemid 23040853)
20. Tzankov A., Heiss S., Ebner S., Sterlacci W., Schaefer G., Augustin F., Fiegl M., Dirnhofer S., Angiogenesis in nodal B cell lymphomas: a high throughput study Journal of Clinical Pathology 2007 60 5 476 482 (Pubitemid 46867154)
21. Ganjoo K. N., Moore A. M., Orazi A., Sen J. A., Johnson C. S., An C. S., The importance of angiogenesis markers in the outcome of patients with diffuse large B cell lymphoma: a retrospective study of 97 patients Journal of Cancer Research and Clinical Oncology 2008 134 3 381 387 (Pubitemid 351170060)